

DARPA BioComp Plasmid Distribution 1.00 of Standard Biobrick Components

Tom Knight (tk@ai.mit.edu)

MIT Artificial Intelligence Laboratory

May 22, 2002

This distribution consists of 300 ng aliquots of plasmid DNA for each of twelve components and compound constructs utilizing our idempotent assembly strategy. The dried DNA should be stable at room temperature for many weeks, but long term storage at -20 or -80 in the resealable foil pouch with desiccant is recommended. This document and much additional information, protocols, and detailed sequences is or will be available from the site <http://ks.ai.mit.edu>

Well number 1 is marked with a red marker. The foil top can be pierced with a pipet tip to add DI water for resuspending the sample. We recommend resuspending in 100 μ l water, and transferring the resuspended sample to another labelled tube for more permanent storage. Standard heat shock or electroporation transformation techniques can be used to introduce the plasmid into E. coli cell lines. Samples were dried down from 10 μ l of TE 10:0.1, so the solution will contain small amounts of Tris and EDTA. For electroporation, it might be necessary to further dilute or dialyze the samples to avoid arcing. Our standard strain for cloning is the Invitrogen library efficiency chemically competent DH5 α strain, catalog number 18263-012. All constructs are based on a pUC18 backbone, and are high copy number and ampicillin resistant. We grow strains in Difco LB Lennox broth or agar with 100 μ g/l of ampicillin (Sigma A0166).

Expression of the lacZ α gene can best be seen on Sigma S-gal plates, which provide a marked improvement over X-gal plates.

Note that the DH5 α strain does not express LacI. Controlled expression of LacI should be done with a construct providing LacI or in a lacI^q strain such as XL1-Blue.

Much of the power of these assembly techniques arise from a consistent, widely available set of components. We strongly encourage others who develop components in this form to contact us with complete information and samples, if possible. We volunteer to act as a community coordination and distribution point for these components as they are developed. If you have components which you believe are useful but not in this form, we may, in many cases, be interested in doing the work necessary to cast them into standard component form.

We are working to develop licenses which would encourage widespread free distribution of DNA components, sequences, and documentation and intend those licenses, as developed, to apply to these components and assembly strategies.

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE 22 MAY 2002		2. REPORT TYPE		3. DATES COVERED 00-05-2002 to 00-05-2002	
4. TITLE AND SUBTITLE DARPA BioComp Plasmid Distribution 1.00 of Standard Biobrick Components				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA, 02139-4307				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES 2	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

Standard Components and Assemblies, May, 2002 Distribution

1. pSB103
Base plasmid for the Biobrick idempotent assembly technique.
2. pSB103-Plac
Plasmid containing the Plac promoter. CAP and LacI repressor binding sites. Wild type sequence.
3. pSB103-lacZ α
Plasmid containing the lacZ α coding sequence and an upstream ribosomal binding site. This is the alpha complementation portion of the wild type gene, missing the multiple cloning site introduced by Messing.
4. pSB103-ECFP
Plasmid containing the Clontech ECFP gene and an upstream ribosomal binding site.
5. pSB103-EYFP
Plasmid containing the Clontech EYFP gene and an upstream ribosomal binding site. A silent mutation to eliminate the PstI cut site within the coding sequence has been introduced to conform with standard biobrick assembly standards.
6. pSB103-T1
Plasmid containing the rrnB-T1 transcriptional terminator.
7. pSB103-Plac-ECFP
Plasmid expressing the ECFP gene from the Plac promoter.
8. pSB103-Plac-EYFP
Plasmid expressing the EYFP gene from the Plac promoter.
9. pSB103-Plac-ECFP-EYFP
Plasmid expressing both the ECFP and EYFP genes from the Plac promoter.
10. pSB103-Plac-EYFP-ECFP
Plasmid expressing both the EYFP and ECFP genes (opposite order) from the Plac promoter.
11. pSB103-Plac-ECFP-T1-EYFP
Plasmid expressing ECFP with dramatically reduced EYFP expression due to the T1 terminator.
12. pSB103-Plac-EYFP-T1-ECFP
Plasmid expressing EYFP with dramatically reduced ECFP expression due to the T1 terminator.

This work is supported by the DARPA/ONR contract "Computing with Synthetic Biology."